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Gene fusions have been discussed in the scientific literature since they were first detected in cancer cells in the early 1980s. There is
currently no standardized way to denote the genes involved in fusions, but in the majority of publications the gene symbols in
question are listed either separated by a hyphen (-) or by a forward slash (/). Both types of designation suffer from important
shortcomings. HGNC has worked with the scientific community to determine a new, instantly recognizable and unique separator—
a double colon (::)—to be used in the description of fusion genes, and advocates its usage in all databases and articles describing
gene fusions.
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BRIEF HISTORICAL BACKGROUND OF GENE FUSIONS
Technical developments at the end of the 1970s enabled the
identification of genes in the breakpoints of chromosome
rearrangements, which in the early 1980s led to the discovery
and characterization of gene fusions in neoplasia. While the
products of translocation events are referred to by several terms,
including fusion genes, hybrid genes and chimeric genes, here we
largely choose to use the term fusion genes as this is most widely
used in this context. Analyses of the recurrent balanced
translocations in Burkitt lymphoma (BL) and chronic myeloid
leukemia (CML) proved particularly pivotal. The picture to emerge
was that reciprocal translocations exert their effects by one of two
alternative mechanisms: deregulation, usually resulting in the
overexpression of a seemingly normal gene in one of the
breakpoints, or the creation of a hybrid, chimeric gene through
fusion of parts of two genes, one in each breakpoint [1] (see
Fig. 1).
BL provided the first conclusive evidence for the deregulation
mechanism. This tumor type was found to harbor one of three
translocations: t(8;14)(q24;q32), t(2;8)(p11;q24) or t(8;22)(q24;q11).
In all three, the breakpoints in chromosome 8 were found to be
within or adjacent to the MYC oncogene (8q24), and the other
breakpoint in an immunoglobulin gene, encoding the heavy chain
(IGH in 14q32) or the kappa (IGK in 2p11) or lambda (IGL in 22q11)
light chains [2–4]. As a consequence of these translocations, the
MYC gene becomes transcriptionally deregulated, often over-
expressed, owing to the influence of regulatory elements of the
immunoglobulin genes.
The alternative mechanism, the creation of a hybrid gene, was
documented at the same time in CML with the demonstration that
the Philadelphia chromosome, i.e., the derivative chromosome 22
resulting from the recurrent reciprocal translocation t(9;22)(q34;
q11), juxtaposed the 5′ part of the BCR gene at 22q11 with the 3′
part of the ABL1 tyrosine kinase-encoding gene from 9q34. This
leads to an in-frame fusion of parts of the two genes and results in
an abnormal protein, which displays increased tyrosine kinase
activity [5–8] (see Fig. 1).
These and similar molecular insights into how cancer-specific
chromosomal abnormalities act pathogenetically sparked an
enormous interest in cytogenetics as a powerful means to
pinpoint the locations of genes important in tumorigenesis, and
an impressive amount of information has been accumulated
through these efforts. Almost 1000 gene fusions have been found
by genomic characterization of breakpoints in cytogenetically
identified aberrations, balanced as well as unbalanced, in various
leukemias, lymphomas, and solid tumors. The accumulated data
have shown that the consequences of practically all gene fusions
are in principle the same as those originally elucidated in BL and
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CML, i.e., deregulation of a seemingly normal gene or the creation
of a hybrid gene. However, not all gene fusions have translational
consequences, and some could result in gene inactivation
[1, 9, 10].
The advent of massively parallel sequencing (MPS) has recently
provided a radically new means to identify fusions at the DNA or
RNA levels without any prior information on the cytogenetic features
of the neoplastic cells. The results of such unbiased gene fusion
detection efforts during the last decade have dramatically changed
the gene fusion landscape. More than 30,000 gene fusions, the great
majority involving previously unsuspected genes, have now been
identified through deep sequencing in a wide variety of neoplasms
and these are reported in a number of online resources, e.g., https://
mitelmandatabase.isb-cgc.org/, http://atlasgeneticsoncology.org/,
https://cancer.sanger.ac.uk/cosmic, https://ccsm.uth.edu/FusionGDB/,
http://www.kobic.re.kr/chimerdb/, https://tumorfusions.org/. A major
challenge will be to verify by functional studies which of the alleged
gene fusions are pathogenetically important in carcinogenesis, and
which are either secondary progressional changes or non-
consequential “noise” abnormalities, e.g., by-products of the genetic
instability that characterizes many cancer cells. It is important to note
that while gene fusions are a hallmark of neoplasia, they can also
occur in heritable disorders such as the formation of the Lepore and
anti-Lepore haemoglobins from the HBD and HBB genes [11].
There has never been a generally recommended, standardized
way to denote gene fusions. Instead, multiple notations have been
used with varying popularity over time, though the most common
designation is SYMBOL-SYMBOL followed by SYMBOL/SYMBOL,
both of which we critique below.
PROBLEMS WITH THE NOMENCLATURE USED TO DESCRIBE
GENE FUSIONS
The SYMBOL-SYMBOL notation, e.g., BCR-ABL1, to denote fusion
genes has three important shortcomings:
(1) The HGNC has approved the use of the hyphen separator, in
collaboration with all contributing genome annotation groups
involved in the Consensus Coding Sequence (CCDS) Project [12],
for denoting readthrough transcripts, e.g., INS-IGF2.
(2) A hyphen is often used in the literature to denote members
of a complex, e.g., MRE11-NBN, MRE11-RAD50-NBN.
(3) There are also specific groups of approved gene symbols
containing hyphens as separators within the symbol, e.g., TRX-
CAT1-2.
Hence, it is difficult to search specifically for gene fusions in
databases and in the literature using the hyphen symbol.
The SYMBOL/SYMBOL notation, e.g., BCR/ABL1, has at least four
major disadvantages:
(1) The forward slash is an accepted symbol in the established
cytogenetic International System for Human Cytogenomic
Nomenclature (ISCN) to denote different clones, both constitu-
tionally (mosaicism) and in cancer cells; the Human Genome
Variation Society (HGVS) guidelines (https://varnomen.hgvs.org/
recommendations/general/) also use a forward slash to indicate
mosaicism [13].
(2) The forward slash is often used in the literature in place of
“either/or”, e.g., BRCA1/2, and to denote involvement of alternative
genes in a fusion, e.g., “SS18-SSX1/SSX2”.
(3) Pathway and complex descriptions use this character, e.g.,
RAS/RAF/MAPK.
Fig. 1 The chromosomal basis of gene fusions. a Gene fusions may originate through balanced and unbalanced chromosome
rearrangements. Balanced changes comprise translocations (the transfer of chromosome segments between chromosomes), insertions (a
chromosome segment in a new interstitial position in the same or another chromosome) and inversions (rotation of a chromosome segment
by 180°); an example of an unbalanced change is the deletion of an interstitial chromosomal segment. Small arrows indicate breakpoints, and
large arrows indicate the resulting rearranged chromosomes. A and B signify affected genes. Note that a reciprocal gene fusion may be
generated on the partner derivative chromosome as a result of a reciprocal translocation, but this is not shown. b Both balanced and
unbalanced aberrations may lead to the deregulation of either gene A or gene B by the juxtaposition of the coding sequences with the
regulatory sequences of the other gene, or to the creation of a chimeric gene through the fusion of parts of both genes.
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(4) Commercial dual fusion fluorescence in situ hybridization
translocation probes (CE marked) also use a forward slash to
indicate the two probe sets used, e.g., BCR/ABL1.
In view of the considerations listed above, and hence the clear
need for a standardized and unique way to denote gene fusions,
the HGNC concluded that an alternative needed to be sought to
replace the use of either a hyphen (-) or a forward slash (/).
RECOMMENDED NEW NOMENCLATURE TO DESCRIBE GENE
FUSIONS
After careful deliberation, and consultations with experts in the
field, HGNC recommends that a new separator—a double colon
(::)—be used in describing gene fusions, e.g., BCR::ABL1. The
double colon (::) has several important advantages:
First, it follows the long-standing recommendation of the
internationally accepted ISCN cytogenetic nomenclature in which
a single colon (:) is used to indicate a chromosome break and a
double colon (::) to denote break and reunion [14]. The:: separator
thus nicely reflects the principal mode of origin of most fusion
genes. We are aware that fusion transcripts may occasionally
originate at the RNA level through cis- or trans-splicing without a
genomic breakage and reunion correlate, but we deem it
unnecessary to create a different nomenclature system for such
events, especially since the HGVS already recommends using the
double colon to describe RNA fusion transcripts (https://
varnomen.hgvs.org/recommendations/general/).
Secondly, it is instantly recognizable and creates a unique
symbol in the existing gene nomenclature, and hence is easily
searchable in databases and in the literature.
Thirdly, different gene fusions found in different single cells or
in separate clones within the same tumor will be easily
recognizable, i.e., SYMBOL::SYMBOL/SYMBOL::SYMBOL.
SPECIFIC RECOMMENDATIONS WHEN DESCRIBING GENE
FUSIONS
In line with established HGNC recommendations [15], genes
involved in fusions should be designated by their HGNC approved
gene symbols written in italics, whereas proteins are not italicized,
e.g., BCR::ABL1 denotes a fusion of the BCR and ABL1 genes, while
BCR::ABL1 designates the corresponding protein product. By
convention, fusion transcripts identified at the RNA level, e.g., by
RNA-seq, are designated as genes, i.e., in italics. The double colon
(::) should be used for all types of gene fusions, i.e., both those
giving rise to a hybrid, chimeric gene (BCR::ABL1) and those where
regulatory elements from one gene deregulate a partner gene
(IGH::MYC).
In accordance with established practice in designating gene
fusions, the 5′ partner gene should always be listed first in the
description of a fusion gene, i.e., before the double colon,
irrespective of chromosomal location or the orientation of the gene.
Thus, in the BCR::ABL1 fusion gene—the outcome of the transloca-
tion t(9;22)(q34.1;q11.2)—the BCR gene in chromosome 22 is the 5′
gene, the ABL1 gene from chromosome 9 is the 3′ gene.
In tables in scientific articles and in databases presenting gene
fusions, the two genes are often designated either as “Gene A”
and “Gene B” or “Gene 1” and “Gene 2”. Thus, it is not explicitly
stated that “Gene A” or “Gene 1” represents the 5′ gene although
this is usually the case. To avoid ambiguous interpretations, HGNC
recommends that 5′ and 3′ genes be clearly indicated in tables
showing gene fusions. In fusions giving rise to a deregulated gene
the regulatory or enhancer element should be listed first,
whenever known.
If one of the genes in a fusion is unknown this may be indicated
by either a question mark (?) or by the chromosomal band where
the breakpoint is located, following ISCN convention. If one of the
breakpoints lies in an intergenic region and the genomic
coordinate of that breakpoint is known, this can be denoted in
an abbreviated format for publication as chr#:g.coordinate
number. For example, ABL1::? denotes a fusion between ABL1
and an unknown gene, 6q25::ABL1 a fusion between an unknown
gene located in chromosome band 6q25 and ABL1, and ABL1::
chr11.g:1850000 a fusion between ABL1 and a breakpoint at
nucleotide 1,850,000 on chromosome 11. In the first and third
examples the unknown gene and intergenic region are the 3′
partners, and in the second example the unknown gene is the 5′
partner. Full ISCN [14] (https://iscn.karger.com/) or HGVS (https://
varnomen.hgvs.org/recommendations/DNA/variant/complex/)
nomenclature should be used for formal reporting.
Note that HGNC always advocate listing a stable gene ID, ideally
an HGNC ID, when referencing genes in publications. We do not
recommend that the IDs be included in the fusion notation, but
rather in the accompanying text, e.g., a gene fusion involving BCR
(HGNC:1014) and ABL1(HGNC:76) is denoted as BCR::ABL1.
CONCLUSIONS
There has long been a need for a unique, standardized and easily
recognizable way to symbolize gene fusion events consistently, both
in the literature and in databases. Following consultation with
experts in the field of gene fusions, HGNC recommends the use of
the separator “::”, a double colon, between approved gene symbols,
to designate the genes involved in gene fusion events, e.g., BCR::
ABL1. This recommendation is further endorsed by all the authors of
this manuscript, by the HGVS and the ISCN, and by the following
resources: the WHO Classification of Tumors, COSMIC, OMIM, Atlas of
Genetics and Cytogenetics in Oncology and Haematology, Mitelman
Database of Chromosome Aberrations and Gene Fusions in Cancer,
and the Tumor Fusion Gene Data Portal. We urge all readers to use
and publicize this form of notation for describing gene fusions in all
future communications to avoid confusion. We recognize that this is
a newly established recommendation that could be further
developed in due course, and welcome feedback from the
community (via the HGNC website, www.genenames.org).
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